Skip to main content
. 2019 Sep 27;18(6):5811–5820. doi: 10.3892/ol.2019.10929

Figure 3.

Figure 3.

Association between progression-free survival and number of administered VTD cycles. VTD, bortezomib, thalidomide, dexamethasone.